CLINICAL TRIALS PROFILE FOR BUPIVACAINE; MELOXICAM
✉ Email this page to a colleague
All Clinical Trials for BUPIVACAINE; MELOXICAM
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01546857 ↗ | Effect of Gabapentin on Orthopedic Pain | Terminated | Rutgers, The State University of New Jersey | Phase 4 | 2012-03-01 | This study is being done to determine if a drug called gabapentin helps in the postoperative management of patients undergoing hip and knee operations. The investigators wish to determine the effect of gabapentin on pain and sleep following surgery. If we can lessen a patient's pain and improve sleep, the patient will be better able to participate in their physical therapy. Gabapentin has already been shown to lessen postoperative pain when given before surgery. In healthy patients, it has also been shown to improve certain aspects of sleep. We hope to identify the effect of the drug, when given after surgery, on patients' pain and sleep. |
| NCT04538391 ↗ | Intra Incisional Infiltration of Bupivacaine Versus Meloxicam on Post Cesarean Section Pain Relief | Completed | Menoufia University | N/A | 2019-03-03 | Investigation: compare the effect of local infiltration of incision site with bupivacaine and local infiltration with meloxicam in women undergoing cesarean sections on postoperative pain relief and analgesic requirement. Condition: post cesarean sections analgesia intervention: infiltration of incision bupivacaine versus meloxicam Phase: Not applicable |
| NCT05188053 ↗ | Periarticular Bupivacaine + Meloxicam ER Solution Versus Standard Practice During Total Knee Arthroplasty | Enrolling by invitation | Mayo Clinic | Phase 4 | 2022-01-01 | The purpose of this study is to compare an FDA-approved medication for post-operative pain control (HTX-011) to the standard of care institutional practice for periarticular analgesia after primary total knee arthroplasty (weight based dosing of Ropivacaine, epinephrine and ketorolac diluted with saline). We are doing this research study to find out if this new medication provides superior pain control within 72 hours following surgery. |
| NCT05644496 ↗ | ZYNRELEF for Pain Management in Total Knee Arthroplasty | Not yet recruiting | Baptist Health South Florida | Phase 4 | 2023-01-01 | The goal of this randomized controlled trial is to compare opioid medication consumption after surgery for patients who have a total knee replacement. The main questions it aims to answer are: - How well does the study drug control pain in the days after surgery? - Does the study drug reduce the amount of opioid analgesic consumed after surgery? Participants in the study group will undergo a total knee replacement as planned with their surgeon. In addition, be given the study drug, Zynrelef (combination of bupivacaine and meloxicam). Researchers will compare the above to a control group who will have a total knee replace only according to usual standards to see if there are any differences in the amount of a type of pain medication (opioid analgesic) consumed in the days following surgery. |
| NCT05702827 ↗ | Use of a Dual-agent Local Analgesic (Bupivacaine-meloxicam) for Abdominal Incisions in Patients Undergoing Retropubic Mid-urethral Sling Surgery | Not yet recruiting | TriHealth Inc. | Phase 3 | 2023-01-01 | This study will compare the use of a dual-agent local analgesic (bupivacaine-meloxicam) for abdominal incisions in patients undergoing retropubic mid-urethral sling surgery to see if narcotic usage and pain are impacted. |
| NCT05751421 ↗ | Pain Relief After PrimaryTKA | Enrolling by invitation | Rothman Institute Orthopaedics | Phase 3 | 2023-02-28 | While a majority of people who undergo TKA have significant long-term improvement in functional ability, many patients may experience significant pain in the early postoperative period, which may adversely impact postoperative rehabilitation and recovery. Traditionally, opioid medications have been used to control postoperative pain. However, there are many risks with using opioid medications, including addiction and overdose, which kills over 48,000 people yearly. In an effort to overcome this, opioid-sparing multimodal analgesia (MMA) regimens have been developed, commonly using nonsteroid anti-inflammatory drugs (NSAIDs), acetaminophen, regional nerve blocks, and local anesthesia. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for BUPIVACAINE; MELOXICAM
Condition Name
Clinical Trial Locations for BUPIVACAINE; MELOXICAM
Trials by Country
Clinical Trial Progress for BUPIVACAINE; MELOXICAM
Clinical Trial Phase
Clinical Trial Sponsors for BUPIVACAINE; MELOXICAM
Sponsor Name
